Sutro Biopharma Inc. Common Stock (STRO)

About STRO

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including no…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

128

Website

www.sutrobio.com/

Fundamentals

1-day range

$21.7$23.45

Market cap

$400.18M

P/E (trailing)

—

P/E (forward)

-3.26

EPS (trailing)

$-16.35

Dividend yield

—

Beta

1.46

Avg. volume

364.6K

Forecasts

13 analyst ratings

Sutro Biopharma Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• STRO

  Sutro Biopharma Inc. Common Stock

  $20.42

  ▼ 4.18%
  Market cap $400.18MP/E —
  $7.15$43.85
• XFOR

  X4 Pharmaceuticals Inc. Common Stock

  $4.05

  ▼ 4.26%
  Market cap $393.31MP/E 3.24
  $2.8$4.83
• OCGN

  Ocugen Inc. Common Stock

  $1.32

  ▼ 3.65%
  Market cap $420.50MP/E —
  $1$2.73
• FENC

  Fennec Pharmaceuticals Inc. Common Stock

  $12.19

  ▲ 3.57%
  Market cap $378.17MP/E —
  $5.65$13.25
• PALI

  Palisade Bio Inc. Common Stock

  $2.01

  ▼ 4.74%
  Market cap $362.78MP/E —
  $0.53$2.86
• LXEO

  Lexeo Therapeutics Inc. Common Stock

  $4.87

  ▼ 2.51%
  Market cap $357.27MP/E —
  $3.99$10.99
• CABA

  Cabaletta Bio Inc. Common Stock

  $3.11

  ▼ 7.99%
  Market cap $450.03MP/E —
  $1.4$4.23

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34
  Benzinga · 8/13/2026
• Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target
  Benzinga · 8/13/2026
• The market is filled with gapping stocks in Wednesday's session.
  ChartMill · 8/12/2026
• Why is Sutro Biopharma Stock Falling On Wednesday?
  Benzinga · 8/12/2026
• 12 Health Care Stocks Moving In Wednesday's Intraday Session
  Benzinga · 8/12/2026
• Gold Gains 1%; Performance Food Group Shares Fall After Q4 Results
  Benzinga · 8/12/2026
• Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate
  Benzinga · 8/12/2026

• Hunter Heidi · June 5, 2026 · Grant

  10.0K
• Dybbs Michael · June 5, 2026 · Grant

  10.0K
• Wigginton Jon Marc · June 5, 2026 · Grant

  10.0K
• Jagpal Sukhi · June 5, 2026 · Grant

  10.0K
• Lobacki Joseph M · June 5, 2026 · Grant

  10.0K
• Petree Daniel H · June 5, 2026 · Grant

  10.0K
• Connie Matsui · June 5, 2026 · Grant

  10.0K
• PANEK JAMES P · June 5, 2026 · Grant

  10.0K
• Gregory K. Chow · June 2, 2026 · Option Exercise

  2.5K
• David Pauling · March 4, 2026 · Option Exercise

  675
• David Pauling · March 4, 2026 · Tax Withholding

  277 @ $21.31
• Jane Chung · March 4, 2026 · Option Exercise

  788
• Jane Chung · March 4, 2026 · Tax Withholding

  282 @ $21.31
• David Pauling · March 2, 2026 · Grant

  33.6K
• David Pauling · March 2, 2026 · Grant

  4.2K

Institutional Ownership

March 31, 2026

Total shares held

14.05M

Total value held

$341.08M

Institutional holders

69